M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastatic Breast Carcinoma
Invasive Breast Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2013-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00429182

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Dasatinib in Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer
Solid Tumors

Interventions: Drug: Dasatinib
Drug: Gemcitabine

First Posted Date: 2007-01-31

Last Posted Date: 2013-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00429234

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Renal Cell Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00429026

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Phase 1

Completed

Conditions: Advanced Malignancy
Myeloma
Solid Tumors
Lymphoma

Interventions: Drug: Bevacizumab
Drug: Bortezomib

First Posted Date: 2007-01-30

Last Posted Date: 2013-02-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 104

Registration Number: NCT00428545

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Using Focus Groups to Assess the Impact of Environmental Health Science Programs for K-12 Educational Community

Completed

Conditions: Healthy

Interventions: Behavioral: Focus Group Discussion

First Posted Date: 2007-01-30

Last Posted Date: 2012-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00428402

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Not Applicable

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Antithymocyte Globulin

First Posted Date: 2007-01-29

Last Posted Date: 2011-10-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00427336

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: Busulfan
Drug: Melphalan

First Posted Date: 2007-01-29

Last Posted Date: 2012-01-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 168

Registration Number: NCT00427765

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Cellular Therapy With Cord Blood Cells

Phase 2

Completed

Conditions: Multiple Myeloma
Leukemia
Lymphoma

Interventions: Drug: Fludarabine
Drug: Melphalan
Procedure: Umbilical Cord Blood
Drug: Rituximab
Other: Peripheral Blood Stem Cell Infusion

First Posted Date: 2007-01-29

Last Posted Date: 2012-05-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00427557

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Etoposide
Radiation: Total Body Irradiation
Drug: Rituximab

First Posted Date: 2007-01-29

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00427791

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Proton Therapy and Bevacizumab for Primary Liver Tumors

Phase 1

Terminated

Conditions: Liver Cancer
Hepatocellular Carcinoma
Cholangiocarcinoma

Interventions: Drug: Bevacizumab
Radiation: Proton Radiation Therapy

First Posted Date: 2007-01-25

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00426829

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy